Odyssey Therapeutics has appointed Nia Tatsis, Ph.D., Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals, to its Board of Directors1345.
Dr. Tatsis brings over 20 years of experience in regulatory affairs and quality assurance at major biopharmaceutical companies, including Vertex, Sanofi, Stemnion, Pfizer and Wyeth1.
She is recognized for senior-level leadership and has previously served on the Board of Verve Therapeutics and is on the Leadership Council for the International Institute of New England1.
Odyssey’s CEO Gary D. Glick highlighted Dr. Tatsis’s clinical, regulatory, manufacturing, and commercialization experience as critical to advancing the company’s pipeline, including its clinical-stage RIPK2 scaffolding inhibitor1.
Odyssey Therapeutics develops medicines targeting autoimmune and inflammatory diseases, with its first internally discovered therapies reaching multiple clinical milestones in its first few years1.
Dr. Tatsis holds a B.S. in Biology from Temple University and a Ph.D. in Cell and Molecular Biology from the University of Vermont, with postdoctoral work in immunology at Thomas Jefferson University1.
Sources:
1. https://www.businesswire.com/news/home/20251009506187/en/Odyssey-Therapeutics-Appoints-Pharmaceutical-Leader-Nia-Tatsis-Ph.D.-to-Its-Board-of-Directors
3. https://www.citybiz.co/channel/ceo-board/page/1166/
4. https://markets.financialcontent.com/wral/news/publisher/odyssey%20therapeutics,%20inc.